#clinical_trials
12 articles
Biotech Equities
Artiva Biotherapeutics Faces Capital Crunch Before Pivotal NK Cell Therapy Trials
ViaNews Editorial Team (Markets)•
Equity Risk
Cardiff Oncology burns $12M quarterly with only 5 quarters of cash remaining
ViaNews Editorial Team (Markets)•
Earnings & Corporate Events
Cardiff Oncology CEO Faces FDA Trial Endpoint Risk as Q1 Data Nears
ViaNews Editorial Team (Markets)•
Biotech Equities
Kyntra Bio faces catastrophic risk as FG-3246 oncology trial failure looms
ViaNews Editorial Team (Markets)•
Biotech Equities
Anebulo Pharmaceuticals Faces Pipeline Concentration Risk With Single-Asset Strategy
ViaNews Editorial Team (Markets)•
Pharmaceutical Stock Risk
LeonaBio Stock Faces Binary Event: ELAINE-3 Trial Holds Company's Entire Future
ViaNews Editorial Team (Markets)•
Healthcare Equities
Jade Biosciences JADE301 Phase 1 Trial Set for March 2027 Start in Autoimmune Space
ViaNews Editorial Team (Markets)•
Analysis
Four Immunotherapy Companies Race Toward 2026 Launches as Next-Generation Cancer Treatments Near Market
ViaNews Editorial Team (Markets)•
Analysis
Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle
ViaNews Editorial Team (Markets)•